In clinical trials
Digestive & weight
Cagrilintide
Evidence
Clinical trials
Class
Long-acting amylin analog
KEY TAKEAWAY
Cagrilintide is a long-acting analog of amylin, a hormone released with insulin after meals. Novo Nordisk is developing it for weight management. Cagrilintide is not FDA-approved as a standalone drug and is being studied in clinical trials.
Written by the Veylo editorial team · Updated
November 2026
What it is
Long-acting amylin analog
Being studied for
Studied for obesity, alone and with semaglutide
Key fact
Cagrilintide is not FDA-approved as a standalone drug and is being studied in clinical trials.
Route
Weekly subcutaneous injection in trials
Evidence strength
Clinical trials
Cagrilintide is a long-acting analog of amylin, a hormone released with insulin after meals. Novo Nordisk is developing it for weight management.
It acts on amylin and calcitonin receptors in the brain to increase fullness and slow stomach emptying.
Cagrilintide is not FDA-approved as a standalone drug and is being studied in clinical trials.
Studied for obesity, alone and with semaglutide.
Nausea, vomiting and injection-site reactions were the most common effects in trials.
Cagrilintide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.